Sagimet Biosciences Inc. (SGMT) Latest Company News

Aug 17, 2026, 08:02 UTC
Sagimet Biosciences plans to begin a Phase III study of denifanstat for moderate-to-severe acne in the U.S. within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis.
Source:
- marketbeat.com
Aug 13, 2026, 11:00 UTC
Sagimet Biosciences received an FDA 'Study May Proceed' letter and IND clearance for its Phase 3 trial of denifanstat in moderate to severe acne in adolescent and adult patients in the U.S.
Source:
- globenewswire.com
Aug 11, 2026, 00:00 UTC
Sagimet Biosciences Inc. reported a net loss of $14.0 million for Q2 2026, with diluted EPS of -$0.26, and total assets of $263.4 million as of June 30, 2026.
Jun 12, 2026, 00:00 UTC
George Kemble, Ph.D. was elected as a Class III Director of the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.
Jun 12, 2026, 00:00 UTC
David Happel was elected as a Class III Director of the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.
Jun 12, 2026, 00:00 UTC
Anne Phillips, M.D. was elected as a Class III Director of the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.
Jun 12, 2026, 00:00 UTC
Jennifer Jarrett was elected as a Class III Director of the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.
Jun 12, 2026, 00:00 UTC
Tim Walbert resigned from the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.
Jun 3, 2026, 00:00 UTC
Sagimet Biosciences granted equity awards to President and CEO David Happel, CFO Thierry Chauche, and Chief Legal and Administrative Officer Elizabeth Rozek, effective May 28, 2026.

SGMT

Sagimet Biosciences plans to begin a Phase III study of denifanstat for moderate-to-severe acne in the U.S. within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis.

Sagimet Biosciences received an FDA 'Study May Proceed' letter and IND clearance for its Phase 3 trial of denifanstat in moderate to severe acne in adolescent and adult patients in the U.S.

Sagimet Biosciences Inc. reported a net loss of $14.0 million for Q2 2026, with diluted EPS of -$0.26, and total assets of $263.4 million as of June 30, 2026.

George Kemble, Ph.D. was elected as a Class III Director of the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.

David Happel was elected as a Class III Director of the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.

Anne Phillips, M.D. was elected as a Class III Director of the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.

Jennifer Jarrett was elected as a Class III Director of the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.

Tim Walbert resigned from the Board of Directors of Sagimet Biosciences Inc., effective June 12, 2026.

Sagimet Biosciences granted equity awards to President and CEO David Happel, CFO Thierry Chauche, and Chief Legal and Administrative Officer Elizabeth Rozek, effective May 28, 2026.